Endocrine Oncology
Read Time: 12 mins

Vitamin D and Cancer—A Review

Copy Link
Published Online: Jun 10th 2013 US Endocrinology, 2013;9(1):44-49 DOI:
Authors: Claire F Friedman, Spencer H Bachow
Quick Links:
Article Information

Vitamin D is a steroid hormone that has traditionally been recognized for its role in calcium metabolism and skeletal homeostasis. However, there is growing recognition of its immunomodulatory and anti-tumorigenic effects both in vivo and in vitro. Vitamin D and its receptor form a nuclear receptor-ligand complex that exerts anti-proliferative effects via downstream intracellular signaling. While basic science data for the role of vitamin D in both treating and preventing malignancy have been promising, clinical and epidemiologic data in cancer patients have been mixed. In this paper, we will briefly review the basic science and clinical data for the role of vitamin D in cancer prevention and treatment for the four most common malignancies: breast, prostate, colorectal, and lung cancer.


Vitamin D, breast cancer, colorectal cancer, lung cancer, prostate cancer, cancer prevention


According to the American Cancer Society, in 2013 there will be an estimated 1,660,290 new cancer cases and 580,350 deaths from cancer. Lung, colorectal, breast and prostate cancer are the most common malignancies in the US, accounting for approximately 50 % of new cancer diagnoses. Given the morbidity and mortality of these four malignancies (see Figure 1), researchers are exploring many areas of prevention and treatment, including the role of vitamin D.

According to the American Cancer Society, in 2013 there will be an estimated 1,660,290 new cancer cases and 580,350 deaths from cancer. Lung, colorectal, breast and prostate cancer are the most common malignancies in the US, accounting for approximately 50 % of new cancer diagnoses. Given the morbidity and mortality of these four malignancies (see Figure 1), researchers are exploring many areas of prevention and treatment, including the role of vitamin D.

Vitamin D is a fat-soluble vitamin that regulates bone modeling and calcium metabolism. Although we absorb moderate amounts of the vitamin from foods such as milk and fatty fish, the majority of vitamin D is produced in the body when 7-dehydrocholesterol in the skin is exposed to ultraviolet (UV) B radiation to produce vitamin D3 (cholecalciferol). Vitamin D3 then undergoes two hydroxylation steps: first in the liver to form 25-dihydroxyvitamin D2, the major circulating metabolite, and then primarily in the kidney to produce 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active form. It is estimated that 30–50 % of the adult population is vitamin D deficient.1–3 The most commonly accepted definition of vitamin D deficiency is a serum level of 25-dihydroxyvitamin D2 less than 20 ng/mL. Vitamin D insufficiency is defined as a serum level of 25-dihydroxyvitamin D2 between 20 and 30 ng/mL and a level greater than 30 ng/mL is considered sufficient.4

Active vitamin D is produced in a number of tissues, including the breast, prostate, and colon. This activated vitamin D binds to the vitamin D receptor (VDR) to form a nuclear receptor-ligand complex. This forms a heterodimer with the retinoid-X-receptor (RXR) and can regulate the expression of up to 200 genes, including p21, p27, c-fos, and c-myc.5,6 In preclinical studies, 1,25(OH)2D3 inhibited cell proliferation, induced cell differentiation, promoted apoptosis, and decreased angiogenesis (see Figure 2).5,7,8,9 It is likely that the antiproliferative effects of 1,25(OH)2D3 are mediated in part by stalling the cell cycle at the G1/S checkpoint by increasing inhibitors and reducing activators of the cyclin-dependent kinase (CDK) complexes. This prevents DNA synthesis and cell growth.10,11 In addition, the enzyme 1-α-25-dihydroxyvitamin D3 24-hydroxylase (CYP24) is the primary enzyme responsible for the catabolic inactivation of 1,25(OH)2D3 and is considered a candidate oncogene.12,13

In this paper, we review the recent basic science and clinical research concerning vitamin D and the four most common malignancies: lung, breast, colorectal, and prostate cancer.

Lung Cancer
Lung cancer is the leading cause of mortality from cancer worldwide with only a 10 % survival rate at 5 years.14 There are two main pathologic types of primary lung cancer, small cell (15 % of cases) and non-small cell (NSCLC) (about 85 % of all lung cancer cases). NSCLC has three subtypes: squamous-cell carcinoma, adenocarcinoma, and large-cell lung cancer. Despite advances in early detection and standard treatment, NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Smallcell lung cancer is aggressive and presents with metastatic disease in 60 % of cases. It is highly responsive to chemotherapy and radiotherapy but almost always relapses and is almost universally fatal.

There have been multiple in vitro studies that have established 1,25(OH)2D3 as an inhibitor of lung cancer growth.15,16 Vitamin D demonstrates antiproliferative effects in several epithelial-derived stem cell lines such as the NCI-H82 and NCI-H209 small cell lung carcinoma17 and the EBC-1 and H520 nonsmall cell carcinoma cell lines.18 The exact mechanism of this regulation is still being elucidated. Researchers have also demonstrated that 1,25(OH)2D3 inhibits squamous cell carcinoma (SCC) cell motility, invasion, and metastasis, partially through the promotion of E-cadherin-mediated cell–cell adhesion.19

1,25(OH)2D3 also has demonstrated activity in vivo. As discussed above, CYP24 is considered a candidate oncogene for its intracellular inactivation of 1,25(OH)2D3. Zhang et al. used a selective CYP24 inhibitor compound CTA091 and found that it decreased 1,25(OH)2D3 catabolism and enhanced 1,25(OH)2D3-mediated growth inhibition.20 CYP24A1 overexpression is also associated with decreased survival in lung adenocarcinoma.21

Given the in vitro and in vivo data, researchers have completed several observational trials that have explored the relationship between 1,25(OH)2D3 and lung cancer survival. In a US study of 456 patients with early-stage NSCLC, patients who had 25(OH)D2 levels ≥21.6 ng/mL experienced a significant improvement in survival compared with patients with 25(OH)D2 levels ≤10.2 ng/mL.22 Nuclear expression of the VDR is also associated with increased survival. Srinivasan et al. demonstrated that the 5-year overall survival rates were 59 % for patients with high nuclear VDR expression versus 27 % for low nuclear VDR expression.23 This was correlated by Kim et al. by showing that patients with lung adenocarcinoma whose cells expressed higher levels of VDR had an improved survival (hazard ratio [HR] 0.80, 95 % confidence interval [CI] 0.65–0.99) with evidence of G1 cycle arrest.24 Pilz et al. demonstrated that increased circulating 25(OH)D2 was associated with improved survival in lung cancer patients.25 However, epidemiologic evidence for the efficacy of vitamin D is mixed. Freedman et al. found no association between 25(OH)D2 status and total or lung cancer mortality in 16,818 subjects from the third National Health and Nutrition Examination Survey.26 On further analysis with longer follow up, they even found an increased risk for lung cancer mortality in men with higher circulating vitamin D levels.27

Given the intracellular effects of 1,25(OH)2D3, researchers have explored whether 1,25(OH)2D3 may have a synergistic effect with cytotoxic and targeted treatment. Several studies demonstrate that 1,25-(OH)2D potentiates the cytotoxic effect of taxane and platinum-based chemotherapy in SCC murine models.28,29 In addition, there is evidence that the VDR directly inhibits epidermal growth factor receptor (EGFR) transcriptional activity in breast cancer cells and that is augmented after treatment with 1,25(OH)2D3.30 This may have implications for patients with EGFR mutations that are treated with target therapies such as erlotinib. Ultimately, while there is strong evidence that vitamin D has antineoplastic effects in vitro and in vivo, the epidemiologic evidence for improved survival is mixed. Randomized clinical trials are needed to demonstrate whether vitamin D has a clinically significant benefit for lung cancer patients both for prevention and as an adjuvant treatment.

Breast Cancer
Aside from nonmelanoma skin cancer, breast cancer is the most common cancer among women in the US. In 2009 (the most recent year for which statistics are available), 211,731 women in the US were diagnosed with breast cancer and 40,676 women died from the disease. There are several subtypes of breast cancer that affect both prognosis and treatment. In the US, 75 % of tumors are estrogen receptor positive, 20–25 % of tumors

overexpress a tyrosine kinase known as Her2/neu and 10–15 % of tumors are ‘triple-negative,’ meaning they lack estrogen receptors and do not have an overexpression of her2/neu. These triple-negative cancers have a poorer prognosis compared with other types of breast cancer.

As discussed previously, multiple studies have found an in vitro effect of 1,25(OH)2D3 on breast cancer cell lines including cell-cycle arrest31,32 and regulation of downstream signaling pathways.6 In mice, vitamin D deficiency has also been shown to promote breast cancer metastases to bone. This suggests that 1,25(OH)2D3 may effect the bone microenvironment.33 In addition, similar to lung cancer cell lines, 1,25(OH)2D3 increases the expression of E-cadherin which prevents both invasion and metastasis.34

In 1990, Garland et al. first reported an inverse association between total average annual sunlight energy that strikes the ground and age-adjusted breast cancer mortality in the US, suggesting that vitamin D may have a role in breast cancer tumorigenesis. Subsequent studies have had mixed results. Villaseñor et al. found a decreased risk for overall mortality (ageadjusted HR=0.58; 95 % CI 0.36–0.96) in women with sufficient (>30 ng/ ml) levels of serum vitamin D; however, this effect was attenuated in multivariate analysis (HR=0.90; 95 % CI 0.50–1.61).35

This relationship has also been explored in several large cohort studies. The largest is the Nurse’s Health Study, which included 88,691 women who completed surveys every 4 years including items about vitamin D intake. High vitamin D intake was associated with a statistically significant lower risk for premenopausal breast cancer (odds ratio [OR] 0.72; 95 % CI 0.55–0.94) but not for postmenopausal breast cancer.36 A similar finding was reported in the Women’s Health Initiative Study (WHI). Higher intake of vitamin D was associated with a lower risk for breast cancer in premenopausal women (OR 0.65; 95 % CI 0.42–1.00) but not in postmenopausal women (OR 1.30; 95 % CI 0.97–1.13).37

Researchers have also examined the relationship between serum 1,25(OH)2D3 levels and breast cancer risk, both in prospective cohort studies and case-control studies. The majority of case-control studies found a statistically significant lower risk for breast cancer among women with higher circulating vitamin D levels.38–41 Crew et al. found

that 1,25(OH)2D3 levels above 40 ng/mL are associated with a decreased breast cancer risk (OR 0.56; 95 % CI 0.41–0.78) and this effect was greatest among postmenopausal women, in contrast to the Nurse’s Health Study.42

At this time, there have been only two randomized clinical trials exploring vitamin D levels and the risk of breast cancer. In the WHI, there was no reduction in the risk for breast cancer in women randomly assigned to take calcium (1,000 mg) and vitamin D3 (400 IU) daily versus placebo.43 In another trial of approximately 1,200 postmenopausal women randomized to receive 1,100 IU of vitamin D3 and calcium, calcium alone, or placebo, a 60 % lower risk for cancer of all types, including breast cancer, was observed after 4 years of supplementation with vitamin D3 and calcium (p=0.013).44 Currently, there are several phase II studies looking at whether high-dose vitamin D supplementation (20,000 IU weekly or 30,000 IU weekly) prevents breast cancer in both pre and postmenopausal women at high risk for developing breast cancer.

Lastly, there is some data for utilizing vitamin D in breast cancer treatment. First, in vitro studies have demonstrated that 1,25(OH)2D3 suppresses the estrogen pathway by reducing the expression of the gene coding for aromatase,45 the enzyme that converts androgens to estrogens as well as downregulating expression of estrogen receptor-α (ER-α).46,47 In addition, 1,25(OH)2D3 potentiates the cytotoxic effects of several agents used in breast cancer treatment including adriamycin48 and paclitaxel.49 Several randomized controlled trials are currently enrolling women to examine the effects of high-dose 1,25(OH)2D3 in combination with taxanes.

Colorectal Cancer
Colorectal cancer is the third leading cause of cancer-related death in the US. It is the second leading cause when both sexes are combined. It is expected to cause about 50,830 deaths during 2013.50 Globally, the age-adjusted incidence of colorectal cancer range from 30 or more cases per 100,000 people in North America, certain areas of Europe, Australia, New Zealand, and Japan to less than five cases per 100,000 people in much of Africa and parts of Asia.51 This large disparity among the different geographic regions suggests a role for vitamin D in the development of colorectal cancer.52

In colorectal cancer cell lines, 1,25(OH)2D3 causes growth arrest of colorectal cancer cells. Specifically, 1,25(OH)2D3 induces the expression of CDK inhibitors p21CIP1 and p27KIP1 and represses the action of cyclins A and F.53–56 1,25(OH)2D3 also downregulates the c-myc oncogene via binding the vitamin D response element and by augmenting the expression and binding of intermediate proteins to regulatory regions of the gene.57–60

Vitamin D also modulates apoptosis in colorectal cancer cells. 1,25(OH)2D3 induces the expression of G0S2, which prevents BCL-2 from forming anti-apoptotic heterodimers with the well-known BAX protein.56,62 Furthermore, 1,25(OH)2D3 downregulates the anti-apoptotic protein BAG1 and sensitizes colorectal cancer cells to the cytotoxic agent 5-fluorouracil by downregulating the anti-apoptotic protein survivin.63,64 Additionally, 1,25(OH)2D3 enhances expression of several proteins linked to the formation of tight junctions, adherens junctions, and hemidesmosomes, all crucial in maintaining an epithelial phenotype.56,65,66 This may be crucial in preventing colorectal cancer metastases.

Angiogenesis appears to be regulated by vitamin D in vitro. For example, 1,25(OH)2D3 represses the expression of hypoxia-inducible factor (HIF)-1α and regulates the expression of vascular endothelial growth factor (VEGFA).55,67 1,25(OH)2D3 also represses DICKKOPF-4 (DKK4), a WNT antagonist that promotes invasion and angiogenesis in colorectal carcinoma cultures.68

In colorectal carcinoma cultures, vitamin D has also been found to modify both phase I and II enzymes involved in reduction, oxidation, hydrolysis, and conjugation—all important for the removal of compounds that may contribute to the formation of cancer.69 Furthermore, vitamin D has been showed to regulate the expression of members of the multidrug resistance-associated protein family that are responsible for the efflux of potentially toxic conjugates from the intracellular milieu.70,71

There is a substantial amount of epidemiologic literature that examines the relationship between vitamin D and the risk for colorectal cancer. Garland and Garland published a paper in 1980 that proposed an inverse relation between latitude and colorectal cancer mortality.72 In 1989, an inverse association between vitamin D and colorectal cancer status in the US was established.73 A recent meta-analysis of 35 independent studies confirmed a consistent inverse relationship between serum vitamin D levels and the risk for developing colorectal cancer.74 Additionally, a systematic review of 18 prospective studies that assessed the association of vitamin D intake or serum levels of 25(OH)D2 and the risk for colorectal cancer in approximately 1,000,000 individuals was performed. They found an inverse association between both serum 25(OH)D2 and vitamin D intake and the risk for developing colorectal cancer.75 However, Pereira et al. notes that many epidemiologic studies do not take into account endogenous vitamin D production from UV light exposure and are limited by measurement error from the various dietary assessment methods and food composition tables used to calculate dietary intake.62

There is some clinical trial data on vitamin D supplementation and colorectal cancer, albeit scarce. Trivedi et al. ran the first trial with almost 3,000 older individuals receiving 100,000 IU of 1,25(OH)2D3 or placebo for four months.76 They found no change in the incidence of colorectal cancer or mortality over 5 years. The largest clinical trial to date is the WHI. Close to 40,000 postmenopausal women were randomized to receive calcium and 400 IU/day of 1,25(OH)2D3 versus placebo. Initially, the results did not show a relationship between vitamin D supplementation and the incidence of colorectal cancer.77 However, the dose of vitamin D was relatively low and the compliance among the women in the study was only around 80 %.78 A re-analysis of the WHI data showed concurrent vitamin D and estrogen replacement increased the risk for developing colorectal cancer and treatment with vitamin D in the placebo group significantly decreased the risk for developing colorectal cancer.79 Another re-analysis showed a 17 % nonsignificant reduced risk for developing colorectal cancer in the group supplemented with vitamin D.80

There is a lot of evidence implicating a role for vitamin D in colorectal cancer in vitro and in epidemiologic studies. While the WHI gives us some insight on vitamin D replacement in colorectal cancer, additional clinical trials are needed before vitamin D can become mainstream in colorectal cancer therapy.

Prostate Cancer
Other than skin cancer, prostate cancer is the most common cancer in US men. The American Cancer Society estimates that in 2013, about 238,590 new cases of prostate cancer will be diagnosed and about 29,720 men will die of prostate cancer.50

Many studies have examined the question of whether or not vitamin D plays a role in prostate cancer. This originated when the VDR was found in three cell lines of prostate cancer suggesting a role of the vitamin D pathway in prostate cancer progression.81 Recently, high VDR expression in prostate tumors was shown to be associated with a reduced risk for lethal cancer.82 In addition, normal prostate cells express 1-α-hydroxylase, and prostate cancer cells have been shown to lose 1-α-hydroxylase activity in vitro.83–85 This suggests a relationship between vitamin D and progression to malignancy in prostate cancer cells.

Interestingly, in cells from the LNCaP prostate cancer cell line, which have very low levels of endogenous 1-α-hydroxylase activity, the antiproliferative action of 25(OH)D2 was much less pronounced when compared with calcitriol.85 Barnett and Beer hypothesize in their review article that loss of local prostatic 1-α-hydroxylase may render prostate cancer cells more dependent on circulating 1,25(OH)2D3 rather than on the more abundant 25(OH)D2, which can reduce the prostate cell’s ability to regulate its own growth in response to vitamin D levels.86 This finding was demonstrated after transfection of 1-α-hydroxylase cDNA into a prostate cancer cell line increased 1-α-hydroxylase activity significantly.87 Given this in vitro data, other studies have been performed to examine the correlation between UV light exposure and incidence of prostate cancer or prostate cancer mortality. Of the nine studies that have been performed since 2011, seven of the studies show reduced UV light exposure increases prostate cancer risk.88–94 Additionally, the two studies that did not show an increase in the risk for prostate cancer in the setting of reduced UV light did show a difference in mortality for the season of diagnosis.95,96

Given the mixed UV exposure data, we have found 15 case-cohort or case-control studies examining serum vitamin D and its relationship to prostate cancer risk or mortality. Ten of these studies did not find an association between low vitamin D levels (either 1,25(OH)2D3 or 25(OH) D2) and prostate cancer risk or mortality.97–106 Five studies show an increase in prostate cancer risk or mortality with low vitamin D;107–111 one of them shows a decreased risk for lethal cancer107 and two of them demonstrate an increased risk for aggressive cancer.110,111 Of note, two studies show an increased risk with higher levels of 25(OH)D2108,110 and one study shows a possible increased risk for aggressive cancer with higher levels of 25(OH)D2. 103

While the epidemiologic data is promising for vitamin D as a potential therapy in prostate cancer, the use of 1,25(OH)2D3 comes at a cost of hypercalcemia, which comes with its own set of toxicities. Unfortunately, hypercalcemia is shown in some studies to be associated with either an increase in the risk for prostate cancer/and or an increase in the risk for high-grade prostate cancer.112–118

In an effort to increase efficacy and decrease toxicity, the use of vitamin D and its analogues have been studied in combination with other agents. There are many phase II clinical trials that show calcitriol decreases the levels of prostate-specific antigen.119–124 One of these studies did show an improved survival with a formulation of calcitriol in combination with cytotoxic docetaxel, although the phase II study was stopped early in the setting of excess deaths.125

The in vitro studies and the UV light studies show more of a link between prostate cancer and vitamin D, while the serum studies showed more mixed data. Given the high prevalence of prostate cancer in men around the world, we will likely hear more soon about vitamin D and its association with prostate cancer.

Lung, breast, prostate, and colorectal cancer are the four most common malignancies in the US and an estimated 279,650 people will die from these malignancies in 2013. Both basic scientists and clinical researchers are exploring whether vitamin D has a role in both cancer prevention and treatment. In vivo and in vitro studies are promising, demonstrating that the vitamin D ligand-receptor complex downregulates many intracellular pathways necessary for cellular proliferation. However, the clinical studies have been mixed. While several large studies have shown increased survival rates for breast and lung cancer patients with sufficient vitamin D levels, this has not been replicated in other studies. Vitamin D in colorectal cancer appears promising from studies in vitro, but the clinical studies are not as promising at this time. The UV light studies and serum studies that evaluate vitamin D in prostate cancer are mixed as well. Ultimately, large randomized clinical trials are necessary to demonstrate that vitamin D decreases cancer incidence. While this study is underway for breast cancer, it may be prohibitively expensive to perform for other types of malignancies. Similarly, there are many trials currently underway to explore whether vitamin D may be used to enhance cytotoxic therapy. Ultimately, more data is needed to translate vitamin D’s role in cancer from the bench to the bedside. In the meantime, achieving an adequate vitamin D status should be a goal for everyone and may prove to be beneficial in preventing malignancy.

Article Information:

The authors have no conflicts of interest to declare.


Claire Friedman, MD, 3400 Spruce Street, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, US. E:




1. Tangpricha V, Pearce EN, Chen TC, Holick MF, Vitamin D insufficiency among free-living healthy young adults, Am J Med, 2002;112;659–62.
2. Lips P, A Global Study of Vitamin D Status and Parathyroid Function in Postmenopausal Women with Osteoporosis: Baseline Data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial, J Clin Endocrinol Metab, 2001;86:1212–21.
3. Nesby-O’Dell S, Scanlon KS, Cogswell ME, et al., Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994, Am J Clin Nutr, 2002;76:187–92.
4. Holick MF, Vitamin D Deficiency, N Engl J Med, 2007;357:266– 81.
5. Nagpal S, Na S, Rathnachalam R, Noncalcemic actions of vitamin D receptor ligands, Endocr Rev, 2005;26:662–87.
6. Colston KW, Hansen CM, Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer, Endocr Rel Cancer, 2002;9:45–59.
7. Mantell DJ, Owens PE, Bundred NJ, et al., 1,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo, Circ Res, 2000;87;214–20.
8. Gombart AF, Luong QT, Koeffler HP, Vitamin D Compounds: Activity Against Microbes and Cancer, Anticancer Res, 2006;26:2531–42.
9. Trump DL, Muindi J, Fakih M, et al., Vitamin D Compounds: Clinical Development as Cancer Therapy and Prevention Agents, Anticancer Res, 2006;26:2551–6.
10. Holick MF, Vitamin D: Its role in cancer prevention and treatment, Prog Biophys Mol Bio, 2006;92:49–59.
11. Samuel S, Sitrin MD, Vitamin D’s role in cell proliferation and differentiation, Nutri Rev, 2008;66:S116–24.
12. Albertson DG, Ylstra B, Segraves R, et al., Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene, Nat Genet, 2000;25:144–6.
13. Prosser DE, Jones G, Enzymes involved in the activation and inactivation of vitamin D, Trends Biochem Sci, 2004;29:664–73.
14. Herbst RS, Heymach JV, Lippman SM, Lung Cancer, N Engl J Med, 2008;359:1367–80.
15. Norton R, O’Connell MA, Vitamin D: potential in the prevention and treatment of lung cancer, Anticancer Res, 2012;32:211–21.
16. Nakagawa K, Kawaura A, Kato S, et al., Metastatic growth of lung cancer cells is extremely reduced in Vitamin D receptor knockout mice, J Steroid Biochem Mol Bio, 2004;89–90:545–7.
17. Güzey M, Sattler C, DeLuca HF, Combinational Effects of Vitamin D3and Retinoic Acid (Alltransand 9cis) on Proliferation, Differentiation, and Programmed Cell Death in Two Small Cell Lung Carcinoma Cell Lines, Biochem Biophys Res Commun, 1998;249:735–44.
18. Higashimot Y, Ohata M, Nishio K et al., 1 Alpha, 25-dihydroxyvitamin D-3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line, Anticancer Res, 1996;16(5A):2653–9.
19. Ma Y, et al., Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1a,25- dihydroxycholecalciferol, Cancer, 2013;119:563–74.
20. Zhang Q, Yu WD, Su B, et al., CYP24 inhibition preserves 1α,25-dihydroxyvitamin D3 anti-proliferative signaling in lung cancer cells, Mol Cell Endocrinol, 2012;355:153–61.
21. Chen G, Kim SH, King AN, et al., CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma, Clin Cancer Res, 2011;17:817–26.
22. Zhou W, Heist RS, Liu G, et al., Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients, JCO, 2007;25:479–85.
23. Srinivasan M, Parwani AV, Hershberger PA, et al., Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer, J Steroid Biochem Mol Bio, 2011;123:30–36.
24. Kim SH, Chen G, King AN, et al., Characterization of vitamin D receptor (VDR) in lung adenocarcinoma, Lung Cancer, 2012;77:265–71.
25. Pilz S, Tomaschitz A, Obermayer-Pietsch B, et al., Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res, 2009;29;3699–704.
26. Freedman DM, Looker AC, Chang SC, Graubard BI, Prospective study of serum vitamin D and cancer mortality in the United States, J Natl Cancer Inst, 2007;99:1594–602.
27. Freedman DM, Looker AC, Abnet CC, et al., Serum 25-Hydroxyvitamin D and Cancer Mortality in the NHANES III Study (1988–2006), Cancer Res, 2010;70;8587–8597.
28. Light BW, Yu WD, McElwain MC, et al., Potentiation of Cisplatin Antitumor Activity Using a Vitamin D Analogue in a Murine Squamous Cell Carcinoma Model System, Cancer Res, 1997;57:3759–3764.
29. Hershberger PA, Yu WD, Modzelewski RA, et al., Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis, Clin Cancer Res, 2001;7:1043–51.
30. McGaffin KR, Chrysogelos SA, Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells, J Mol Endocrinol, 2005;35:117–133.
31. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J, Inhibitory Effects of 1α,25-Dihydroxyvitamin D3 on the G1–S Phase-Controlling Machinery, Mol Endocrinol, 2001;15:1370–80.
32. Simboli-Campbell M, Narvaez C, Van Weelden K, et al., Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells, Breast Cancer Res Treat, 1997;42:31–41.
33. Ooi LL, Zhou H, Kalak R, et al., Vitamin D Deficiency Promotes Human Breast Cancer Growth in a Murine Model of Bone Metastasis, Cancer Res, 2010;70:1835–44.
34. Wang Q, Lee D, Sysounthone V, et al., 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects, Breast Cancer Res Treat, 2001;67:157–68.
35. Villaseñor A, Ballard-Barbash R, Ambs A, et al., Associations of serum 25-hydroxyvitamin D with overall and breast cancer–specific mortality in a multiethnic cohort of breast cancer survivors, Cancer Causes Control, 2013;1–9.
36. Shin MH, Holmes MD, Hankinson SE, et al., Intake of Dairy Products, Calcium, and Vitamin D and Risk of Breast Cancer, J Natl Cancer Inst, 2002;94:1301–10.
37. Lin J, Lee I, Cook NR, et al., Intakes of calcium and vitamin D and breast cancer risk in women, Arch Intern Med, 2007;167:1050–59.
38. Abbas S, et al., Serum 25-hydroxyvitamin D and risk of postmenopausal breast cancer—results of a large case–control study, Carcinogenesis, 2008;29:93–99.
39. Abbas S, Chang-Claude J, Linseisen J, Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study, Int J Cancer, 2009;124:250–55.
40. Engel P, Fagherazzi G, Boutten A, et al., Serum 25(OH) Vitamin D and Risk of Breast Cancer: A Nested Case-Control Study from the French E3N Cohort, Cancer Epidemiol Biomarkers Prev, 2010;19:2341–50.
41. Lowe LC, Guy M, Mansi JL, et al., Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population, Eur J Cancer, 2005;41:1164–9.
42. Crew KD, Gammon MD, Steck SE, et al., Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk, Cancer Prev Res, 2009;2:598–604.
43. Prentice RL, Anderson GL, The Women’s Health Initiative: Lessons Learned, Annu Rev Public Health, 2008;29:131–50.
44. Lappe JM, Travers-Gustafson D, Davies KM, et al., Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial, Am J Clin Nutri, 2007;85:1586–91.
45. Krishnan AV, Swami S, Peng L, et al., Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy, Endocrinology, 2010;151:32–42.
46. Stoica A, Saceda M, Fakhro A, et al., Regulation of estrogen receptor-α gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells, J Cell Biochem, 1999;75:640–51.
47. James SY, Mackay AG, Binderup L, Colston KW, Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogenresponsive growth of human breast cancer cells, J Endocrinol, 1994;141:555–63.
48. Chaudhry M, Sundaram S, Gennings C, et al., The vitamin D3 analog, ILX-23-7553, enhances the response to Adriamycin and irradiation in MCF-7 breast tumor cells, Cancer Chemother Pharmacol, 2001;47:429–36.
49. Koshizuka K, Koike M, Asou H, et al., Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo, Breast Cancer Res Treat, 1999;53:113–20.
50. “What are the key statistics about colorectal cancer?” American Cancer Society, 2013. Available at: http://www. colorectal-cancer-key-statistics (accessed January 17, 2013).
51. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 2010;127:2893–917.
52. Zhang X, Giovannucci E, Calcium, vitamin D and colorectal cancer chemoprevention, Best Prac Res Cl Ga, 2011;25:485–94.
53. Evans SR, Soldatenkov V, Shchepotin EB, et al., Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis, Int J Oncol, 1999;14:979–85.
54. Gaschott T, Steinmeyer A, Steinhilber D, et al., ZK 156718, a low calcemic, antiproliferative, and prodiffer- entiating vitamin D analog, Biochem Bioph Res Co, 2002;290:504–9.
55. Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez- Martin A, et al., 1a, 25-Dihydroxyvitamin D 3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells, Oncogene, 2005;6533–44
56. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, et al., Genetic signatures of differentiation induced by 1alpha,25- dihydroxyvitamin D3 in human colon cancer cells, Cancer Res, 2003;63:7799–806.
57. Pan Q, Martell RE, O’Connell TD, Simpson RU, 1,25- Dihydroxyvitamin D3-regulated binding of nuclear proteins to a c-myc intron element, Endocrinology, 1996;137:4154–160.
58. Pan Q, Simpson RU, c-myc intron element-binding proteins are required for 1, 25-dihydroxyvitamin D3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4, J Biochem, 1999;274:8437–44.
59. Toropainen S, Vaisanen S, Heikkinen S, Carlberg C, The down-regulation of the human MYC gene by the nuclear hormone 1a,25-dihydroxyvitamin D3 is associated with cycling of corepressors and histone deacetylases, J Mol Biol, 2010;400:284–94.
60. Meyer MB, Goetsch PD, Pike JW, VDR/RXR and TCF4/b-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression, Mol Endocrinol, 2012;26:37–51.
61. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy, Cancer Res, 2000;60:2304–12.
62. Welch C, Santra MK, El-Assaad W, Zhu X, Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2, Cancer Res, 2009;69:6782–89.
63. Barnes JD, Arhel NJ, Lee SS, Sharp A, Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells, Apoptosis, 2005;10:301–11.
64. Liu G, Hu X, Chakrabarty S, Vitamin D mediates its action in human colon carcinoma cells in a calcium- sensing receptordependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU, Int J Cancer, 2010;126:631–9.
65. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, et al., Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of ß-catenin signaling, J Cell Biol, 2001;154:369–87.
66. Fujita H, Sugimoto K, Inatomi S, et al., Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2C absorption between enterocytes, Mol Biol Cell, 2008;19:1912–21.
67. Ben-Shoshan M, Amir S, Dang DT, Dang LH, et al., 1a,25- Dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells, Mol Cancer Ther, 2007;6:1433–9.
68. Pendas-Franco N, Garcia JM, Pena C, et al., DICKKOPF-4 is induced by TCF/b-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1a,25-dihydroxyvitamin D3, Oncogene, 2008;27:4467–77.
69. Pereira F, Larriba MJ, Munoz A, Vitamin D and colon cancer, Endocr Relat Cancer, 2012;19:R51–71.
70. McCarthy TC, Li X, Sinal CJ, Vitamin D receptor- dependent regulation of colon multidrug resistance- associated protein 3 gene expression by bile acids, J Biol Chem, 2005;280:23232–42.
71. Fan J, Liu S, Du Y, et al., Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1a,25- dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer, J Pharmacol Exp Ther, 2009;330:389–402.
72. Garland CF, Garland FC, Do sunlight and vitamin D reduce the likelihood of colon cancer?, Int J Epidemiol, 1980;3:227–31.
73. Garland CF, Comstock GW, Garland FC, et al., Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study, Lancet, 1989;2:1176–8.
74. Gandini S, Boniol M, Haukka J, et al., Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and color- ectal, breast and prostate cancer and colorectal adenoma, Int J Cancer, 2011;128:1414–24.
75. Ma Y, Zhang P, Wang F, Yang J, et al., Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies, J Clin Oncol, 2011;29:3775–82.
76. Trivedi DP, Doll R, Kahw KT, Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial, BMJ, 2003;326(7387)469.
77. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Calcium plus vitamin D supplementation and the risk of colorectal cancer, N Engl J Med, 2006;354(7):684–96.
78. Zhang X, Giovannucci E, Calcium, vitamin D and colorectal cancer chemoprevention, Best Pract Res Clin Gastroenterol, 2011;25(4–5):485–94.
79. Ding EL, Mehta S, Fawzi WW, Giovannucci EL, Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial, Int J Cancer, 2008;122:1690–94.
80. Bolland MJ, Grey A, Gamble GD, Reid IR, Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set, Am J Clin Nutr, 2011;1144–9.
81. Miller GJ, Stapleton GE, Ferrara JA, et al., The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25- dihydroxyvitaminD3, Cancer Res,1992;52(3):515–20.
82. Hendrickson WK, Flavin R, Kasperzyk JL, et al., Vitamin D receptor protein expression in tumor tissue and prostate cancer progression, J Clin Oncol, 2011;29:2378–85.
83. Schwartz GG, Whitlatch LW, Chen TC, et al., Human prostate cells synthesize 1,25(OH)2D3from 25-hydroxyvitamin D3, Cancer Epidemiol Biomarkers Prev ,1998;7(5):391–5.
84. Chen TC, Wang L, Whitlatch LW, et al., Prostatic 25- hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer, J Cell Biochem, 2003;88(2):315–22.
85. Hsu JY, Feldman D, McNeal JE, et al., Reduced 1alphahydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition, Cancer Res, 2001;61(7):2852–6.
86. Barnett CM, Beer TM, Prostate cancer and vitamin D: what does the evidence really suggest?, Urol Clin N Am, 2011;38:333–42.
87. Whitlatch LW, Young MV, Schwartz GG, et al., 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer, J Steroid Biochem Mol Biol, 2002;81(2): 135–40.
88. Hanchette CL, Schwartz GG, Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation, Cancer, 1992;70(12):2861–9.
89. Luscombe CJ, Fryer AA, French ME, et al., Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer, Lancet, 2001;358(9282):641–2.
90. Grant WB, An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation, Cancer, 2002;94(6):1867–75.
91. Bodiwala D, Luscombe CJ, French ME, et al., Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type, Carcinogenesis, 2003;24(4):711–17.
92. John EM, Schwartz GG, Koo J, et al., Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer, Cancer Res, 2005;65(12):5470–79.
93. Schwartz GG, Hanchette CL, UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States), Cancer Cause Control, 2006;17(8):1091–101.
94. Loke TW, Seyfi D, Khadra M, Prostate cancer incidence in Australia correlates inversely with solar radiation, BJU Int, 2011;108(Suppl. 2):66–70.
95. Robsahm TE, Tretli S, Dahlback A, et al., Vitamin D3 from sunlight may improve the prognosis of breast, colon and prostate cancer (Norway), Cancer Cause Control, 2004;15(2):149–58.
96. Lagunova Z, Porojnicu AC, Dahlback A, et al., Prostate cancer survival is dependent on season of diagnosis, Prostate, 2007;67(12):1362–70.
97. Braun MM, Helzlsouer KJ, Hollis BW, et al., Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States), Cancer Cause Control, 1995;6(3):235–9.
98. Gann PH, Hennekens CH, Hollis BW, et al., Circulating vitamin D metabolites in relation to subsequent development of prostate cancer, Cancer Epidemiol Biomarkers Prev, 1996;5(2):121–6.
99. Nomura AM, Stemmermann GN, Lee J, et al., Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States), Cancer Cause Control, 1998;9(4)425–32.
100. Platz EA, Leitzmann MF, Hollis BW, et al., Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer, Cancer Cause Control, 2004;15(3):255–65.
101. Jacobs ET, Giuliano AR, Martinez ME, et al., Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer, J Steroid Biochem Mol Biol, 2004;89–90(1– 5):533–7.
102. Faupel-Badger JM, Diaw L, Albanes D, et al., Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men, Cancer Epidemiol Biomarkers Prev, 2007;16(12):2784–6.
103. Ahn J, Peters U, Albanes D, et al., Serum vitamin D concentration and prostate cancer risk: a nested casecontrol study, J Natl Cancer Inst, 2008;100(11):796–804.
104. Travis RC, Crowe FL, Allen NE, et al., Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), Am J Epidemiol, 2009;169(10):1223–32.
105. Barnett CM, Nielson CM, Shannon J, et al., Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men, Cancer Cause Control, 2010;21(8):1297–303.
106. Albanes D, Mondul AM, Yu K, et al., Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study, Cancer Epidem Biomar, 2010;20:1850–60.
107. Shui IM, Mucci LA, Kraft P, et al., Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study, J Natl Cancer, 2012;104:690–99.
108. Tuohimaa P, Tenkanen L, Ahonen M, et al., Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries, Int J Cancer, 2004;108(1):104–8.
109. Corder EH, Guess HA, Hulka BS, et al., Vitamin D and prostate cancer: a prediagnostic study with stored sera, Cancer Epidemiol Biomarkers Prev, 1993;2(5):467–72.
110. Ahonen MH, Tenkanen L, Teppo L, et al., Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland), Cancer Cause Control, 2000;11(9):847–52.
111. Li H, Stampfer MJ, Hollis JB, et al., A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer, PLoS Med, 2007;4(3):e103.
112. Chan JM, Giovannucci E, Andersson SO, et al., Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden), Cancer Cause Control, 1998;9(6):559–66.
113. Giovannucci E, Rimm EB, Wolk A, et al., Calcium and fructose intake in relation to risk of prostate cancer, Cancer Res, 1998;58(3):442–7.
114. Skinner HG, Schwartz GG, Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey, Cancer Epidemiol Biomarkers Prev, 2008;17(9):2302–5.
115. Kristal AR, Arnold KB, Neuhouser ML, et al., Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial, Am J Epidemiol, 2010;172(5):566–77.
116. Ahn J, Albanes D, Peters U, et al., Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial, Cancer Epidemiol Biomarkers Prev, 2007;16(12):2623–30.
117. Rodriguez C, McCullough ML, Mondul AM, et al., Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men, Cancer Epidemiol Biomarkers Prev, 2003;12(7):597–603.
118. Kristal AR, Cohen JH, Qu P, et al., Associations of energy, fat, calcium, and vitamin D with prostate cancer risk, Cancer Epidemiol Biomarkers Prev, 2002;11(8):719–25.
119. Beer TM, Ryan CW, Venner PM, et al., Double- blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgenindependent prostate cancer: a report from the ASCENT Investigators, J Clin Oncol, 2007;25(6):669–74.
120. Beer TM, Eilers KM, Garzotto M, et al., Weekly high- dose calcitriol and docetaxel in metastatic androgen- independent prostate cancer, J Clin Oncol, 2003;21(1):123–8.
121. Beer TM, Garzotto M, Katovic NM, High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer, Am J Clin Oncol, 2004;27(5):535–41.
122. Tiffany NM, Ryan CW, Garzotto M, et al., High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study, J Urol, 2005;174(3):888–92.
123. Trump DL, Potter DM, Muindi J, et al., Phase II trial of highdose, intermittent calcitriol (1,25 dihydroxy-vitamin D3) and dexamethasone in androgen- independent prostate cancer, Cancer, 2006;106(10):2136–42.
124. Chan JS, Beer TM, Quinn DI, et al., A phase II study of highdose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer, BJU Int, 2008;102(11):1601–6.

Further Resources

Share this Article
Related Content In Endocrine Oncology
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72